Related Experiment Video

Updated: May 30, 2026

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease
08:51

Application of Unsupervised Multi-Omic Factor Analysis to Uncover Patterns of Variation and Molecular Processes Linked to Cardiovascular Disease

Published on: September 20, 2024

Association between polymorphisms in the coagulation factor VII gene and coronary heart disease risk in different

Xingbo Mo1, Yongchen Hao, Xueli Yang

  • 1Department of Evidence Based Medicine and Division of Population Genetics, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

BMC Medical Genetics
|August 16, 2011
PubMed

Insights

Genetic variations in the factor VII gene are linked to coronary heart disease (CHD) risk. The -323Ins10 polymorphism shows significant association with CHD in Asian and European populations, warranting further investigation.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Epidemiology

Background:

  • Previous studies on factor VII gene polymorphisms and coronary heart disease (CHD) risk have yielded inconclusive results.
  • This study aimed to clarify the association between specific factor VII gene polymorphisms and CHD risk across diverse ethnic groups.

Purpose of the Study:

  • To conduct a meta-analysis assessing the association between factor VII gene polymorphisms (R353Q, HVR4, -323Ins10) and CHD risk.
  • To evaluate ethnic differences in these associations.

Main Methods:

  • A literature-based search was performed to gather relevant case-control studies.
  • Fixed-effects and random-effects models were used to pool odds ratios (OR) and 95% confidence intervals (CI).
  • Publication bias and study heterogeneity were assessed.

Main Results:

  • Thirty-nine studies involving over 9,000 CHD cases and 14,000 controls were analyzed.
  • The -323Ins10 polymorphism showed significant associations with CHD in both Asian (OR=0.74) and European (OR=0.63) populations.
  • The R353Q polymorphism was associated with CHD in Asians (OR=0.70), and HVR4 showed a marginal association (OR=0.88).

Conclusions:

  • The -323Ins10 polymorphism in the factor VII gene is significantly associated with CHD risk in both Asian and European populations.
  • The R353Q polymorphism may be associated with CHD in Asians.
  • No significant association was found for the HVR4 polymorphism; further research is recommended.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...